People: Geron Corp (GERN.OQ)

GERN.OQ on NASDAQ Stock Exchange Global Select Market

2.34USD
12:11pm EDT
Price Change (% chg)

$-0.04 (-1.68%)
Prev Close
$2.38
Open
$2.35
Day's High
$2.36
Day's Low
$2.31
Volume
175,742
Avg. Vol
695,733
52-wk High
$7.34
52-wk Low
$1.31

Search Stocks

Molineaux, Susan 

Brief Biography

Dr. Susan M. Molineaux, Ph.D., has been appointed as Director of Geron Corp., effective September 26, 2012. Dr. Molineaux has more than 20 years of biotechnology industry experience. She has been Chief Executive Officer and President of Calithera Biosciences, Inc., a privately-held biotechnology company developing oncology therapeutics, since co-founding the company in June 2010. Prior to Calithera, Dr. Molineaux co-founded Proteolix, Inc., a privately-held oncology-oriented biopharmaceutical company, where she served as Chief Scientific Officer from December 2003 until December 2005 and from February 2009 until November 2009, and as President and Chief Executive Officer from January 2006 until February 2009. Dr. Molineaux was responsible for leading the development of Proteolix’s second-generation proteasome inhibitor, carfilzomib (now marketed as Kryprolis), for the treatment of multiple myeloma, from discovery through completion of clinical trials for accelerated approval, until the company’s acquisition by Onyx Pharmaceuticals, Inc., a global oncology-oriented biopharmaceutical company, in November 2009. From 2000 to 2003, Dr. Molineaux served as Vice President of Biology at Rigel Pharmaceuticals, Inc., a biopharmaceutical company focused on inflammatory and autoimmune diseases. She served as Vice President of Biology at Praelux, Inc. from 1999 to 2000, and from 1994 through 1999, as Vice President of Drug Development at Praecis Pharmaceuticals, Inc., an oncology-focused biopharmaceutical company. Dr. Molineaux holds a B.S. in biology from Smith College and a Ph.D. in molecular biology from Johns Hopkins University, and completed a postdoctoral fellowship at Columbia University. She currently serves as the Co-Vice Chair of Bay Bio, Northern California’s Life Science Association, and as a member of the board of directors of We Teach Science, a San Francisco Bay Area mentoring program for students in math and science.

Basic Compensation

Total Annual Compensation, Long-Term Incentive Plans, All Other, Fiscal Year Total,
-- -- -- --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Hoyoung Huh

--

John Scarlett

2,278,340

Olivia Bloom

957,156

Stephen Rosenfield

883,374

Andrew Grethlein

866,575

Melissa Kelly Behrs

946,256
As Of 30 Dec 2013
Search Stocks